Company Profile

DiaSorin S.p.A. specializes in the development, manufacturing and marketing of in vitro diagnostic reagents. The products are used in treating infectious and viral diseases, thyroid pathologies, cancer, etc.
At the end of 2023, the group had 10 production sites located in Italy, the United States (6), Canada, Germany, and the United Kingdom.


Source: Cofisem - Last Update: 2024-04-19

Key Executives
Chief Executive Officer Carlo Rosa
Chief Financial Officer Piergiorgio Pedron
Chief Investor Relations Officer Riccardo Fava
Director of Sustainable Development Riccardo Fava
Chief Human Resources Officer Stefano Ronchi


Source: Cofisem - Last Update: 2024-04-19

Key Figures
Millenium 2023 2022 2021 2020 2019
Net sales 1,148,210 1,361,138 1,237,654 881,305 706,319
Income from ordinary activities 1,148,210 1,361,138 1,237,654 881,305 706,319
Operating income 216,261 351,260 419,499 324,226 217,861
Cost of financial indebtedness net 28,291 34,072 22,506 1,375 1,279
Equity-accounted companies contribution to income
Net profit from discontinued activities
Net income 158,508 240,110 310,732 248,296 175,735
Net income (Group share) 159,849 240,907 310,968 247,871 175,735
Fiscal year end 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Length of fiscal year (month) 12 12 12 12 12
Currency & Unit EUR - thousands EUR - thousands EUR - thousands EUR - thousands EUR - thousands
Account Standards IFRS IFRS IFRS IFRS IFRS

Source: Cofisem - Last Update: 2024-04-19

Shareholder information
Chen Menachem Even 4.2 %
Carlo Rosa 8.36 %
Finde SS 44.98 %
Free float 39.43 %
T. Rowe Price Associates, Inc. 3.03 %


Source: Cofisem - Last Update: 2024-04-19

Please contact MyQuestion.Italy@euronext.com for Company Profile support.

Quotazioni, Book, Dividendi, Documenti Societari, Corporate Governance, Internal Dealing di Diasorin


The Exchange accepts no responsability for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.


You will be redirected in five seconds.